Relay Therapeutics launched an underwritten public offering of approximately 22.9 million shares of common stock with an option for underwriters to purchase an additional 3.4 million shares. The offering is expected to raise approximately $996 million in gross proceeds, providing capital for the biopharmaceutical company's pipeline development and operations.